BioLucent Inc. has announced the launch of its SAVI applicator. The SAVI device offers a multicatheter, single-entry approach to breast brachytherapy as part of breast-conserving cancer treatment.
The product introduction will occur at the annual meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO), November 5 through 9 in Philadelphia, PA.
The SAVI applicator is for use in accelerated partial breast irradiation (APBI) after lumpectomy. The applicator is a hybrid of two earlier APBI approaches, combining the tissue-sparing dosimetry of interstitial brachytherapy with the single-entry ease of intracavitary ("balloon") brachytherapy. APBI was developed as an alternative to whole-breast irradiation. Both whole-breast irradiation and APBI are used after breast-conserving surgery to decrease the risk of ipsilateral breast tumor recurrence. The course of daily treatment for whole-breast irradiation is five to seven weeks.

Subscribe Now